Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 ...

Over the last five years, the stock has decreased in 56% of these instances, with a median decline of -3.1% and a maximum ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...

Eli Lilly and Company, a pharmaceutical manufacturing facility, will be receiving up to $100 million in performance-based ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

BRANCHBURG – Eli Lilly, a multinational pharmaceutical company headquartered in Indianapolis with $45 billion in annual sales, has confirmed that it is selling its facility on Imclone Lane off Route ...